All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...
On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a ...
Dogwood Therapeutics, Inc., a clinical-stage biotechnology company, has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) formulation of SP16 to manage cancer related ...
Shares of US clinical-stage biotech Dogwood Therapeutics (Nasdaq: DWTX) soared a massive 43% to $7.91 yesterday, on the news it has secured a royalty free, global license to develop Serpin Pharma’s ...
ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and neuropathy ...
(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) said, in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma's intravenous formulation of SP16 to manage ...
ATLANTA - Dogwood Therapeutics, Inc. (NASDAQ:DWTX), a clinical-stage biotech company with a market capitalization of $10.55 million, has secured a royalty-free global license for Serpin Pharma’s SP16, ...
Glen Dimplex’s main Irish unit slumped to a pretax loss last year as the heating and electrical goods manufacturer announced an overhaul of its operations amid a slowdown in demand for heating pumps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback